The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
This study, in patients with symptomatic chronic obstructive pulmonary disease (COPD), explored switching therapy from non-extrafine high-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA; fluticasone ... (Source: Respiratory Research)
Source: Respiratory Research - October 6, 2023 Category: Respiratory Medicine Authors: Gwen S. Skloot, Alessandro Guasconi, Benjamin R. Lavon, George Georges, Wilfried De Backer, Dmitry Galkin, Mauro Cortellini, Ilaria Panni and Jason H. T. Bates Tags: Research Source Type: research

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
CONCLUSION: Prompt initiation of FF/UMEC/VI following a moderate/severe exacerbation was associated with fewer subsequent exacerbations, fewer hospital readmissions, and lower COPD-related medical costs compared with delayed initiation.PMID:37749551 | DOI:10.1186/s12931-023-02523-1 (Source: Respiratory Care)
Source: Respiratory Care - September 25, 2023 Category: Respiratory Medicine Authors: Afisi S Ismaila Kieran J Rothnie Robert P Wood Victoria L Banks Lucinda J Camidge Alexandrosz Czira Chris Compton Raj Sharma Shannon N Millard Olivia Massey David M G Halpin Source Type: research

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite dual therapy. The optimal timing of triple therapy following an exacerbation of COPD ... (Source: Respiratory Research)
Source: Respiratory Research - September 25, 2023 Category: Respiratory Medicine Authors: Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey and David M. G. Halpin Tags: Research Source Type: research

Cushing's syndrome with inhaled corticosteroid: Drug interactions to avoid
We report the clinical case of a 29-year-old woman with a past history of asthma treated with inhaled fluticasone propionate (FP), chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis (ABPA) treated with itraconazole (ITZ), and Mycobacterium xenopi infection treated with moxifloxacin (MXF), ethambutol (EMB) and clarithromycin (CLR). Four months after initiation of antibiotic and antifungal medication, the patient contracted Cushing's syndrome. Its etiology consisted in interaction between FP, ITZ and CLR, which led to pronouncedly increased corticosteroid concentrations in circulating plasma cells. F...
Source: Revue des Maladies Respiratoires - September 24, 2023 Category: Respiratory Medicine Authors: M Briard C Godet D Mouren G Weisenburger H Mal J Messika M Salpin T Goletto V Bunel M Veyrier Source Type: research

LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - September 22, 2023 Category: Drugs & Pharmacology Source Type: research

Efficacy and safety of fluticasone propionate/salmeterol and fluticasone propionate monotherapy in step-up treatment of childhood asthma: A systematic review and meta-analysis
Asthma, a heterogeneous respiratory disease, is characterized by chronic airway inflammation involving various cellular components such as eosinophils, mast cells, and neutrophils.1 Typical clinical symptoms consist of wheezing, shortness of breath, chest constriction, and coughing. This chronic respiratory disorder is characterized by reversible airway restriction and bronchial hyperreactivity.2,3 Asthma has emerged as one of the most prevalent noncommunicable chronic respiratory diseases affecting children, and its prevalence is rising consistently. (Source: Heart and Lung)
Source: Heart and Lung - September 21, 2023 Category: Intensive Care Authors: Hua Li, Tao Dong, Jinling Luan Source Type: research

Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials
Conclusions This study shows that ML models for causal inference can be used to identify individual response to different COPD treatments and highlight treatment traits. Such models could become clinically useful tools for individual treatment decisions in COPD. (Source: Thorax)
Source: Thorax - September 15, 2023 Category: Respiratory Medicine Authors: Verstraete, K., Gyselinck, I., Huts, H., Das, N., Topalovic, M., De Vos, M., Janssens, W. Tags: Open access, Thorax Chronic obstructive pulmonary disease Source Type: research

Molecules, Vol. 28, Pages 6619: Multi-Residue Detection of Eight Glucocorticoids by Nano-Au/Fluticasone Propionate Electrochemical Immunosensor
o Based on an indirect competitive method, a novel nano-Au/fluticasone propionate electrochemical immunosensor was successfully fabricated by combining the nanoscale effect, superior conductivity of nano-Au, stable Au−S chemical bond as well as strong interaction between glucocorticoid and the receptor, which was used to simultaneously detect eight kinds of glucocorticoids. The modified immunosensors’ electrochemical properties were explored by means of a cyclic voltammetry (CV) method and electrochemical impedance spectroscopy (EIS) measurements. Two factors (glucocorticoid receptor concent...
Source: Molecules - September 14, 2023 Category: Chemistry Authors: Guozheng Zhao Tags: Communication Source Type: research

Understanding the Clinical Implications of Individual Patient Characteristics and Treatment Choice on the Risk of Exacerbation in Asthma Patients with Moderate –Severe Symptoms
ConclusionsIndividual baseline characteristics and treatment choices affect future risk. Achieving comparable levels of symptom control whilst on treatment does not imply comparable risk reduction, as shown by the lower exacerbation rates in FP/SAL vs. BUD/FOR-treated patients. These factors should be considered as a basis for personalised clinical management of patients with moderate –severe asthma. (Source: Advances in Therapy)
Source: Advances in Therapy - September 13, 2023 Category: Drugs & Pharmacology Source Type: research

Azelastine/fluticasone and allergic rhinitis in clinical practice
(Source: European Archives of Oto-Rhino-Laryngology)
Source: European Archives of Oto-Rhino-Laryngology - September 13, 2023 Category: ENT & OMF Source Type: research

Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma and/or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea
ConclusionIn this real-world study, FF/VI administered to Korean patients was well tolerated and effective for the treatment of asthma and COPD. These results were consistent with other studies in Asian and global populations. (Source: Drug Safety)
Source: Drug Safety - August 31, 2023 Category: Drugs & Pharmacology Source Type: research

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
CONCLUSIONS: FP/SAL is a reliable treatment option in patients not achieving control with ICS monotherapy or a different ICS/LABA combination. Evidence shows that FP/SAL is well tolerated and has a similar safety profile to FP monotherapy. Thus, FP/SAL provides an effective option for the management of moderate-to-severe asthma in the paediatric population.PMID:37620110 | DOI:10.1136/bmjresp-2023-001706 (Source: Respiratory Care)
Source: Respiratory Care - August 24, 2023 Category: Respiratory Medicine Authors: Paulo Marcio Pitrez Sira Nanthapisal Ana Paula Beltran Moschione Castro Chirag Teli Abhijith P G Source Type: research

Upper Respiratory Tract OC43 Infection Model for Investigating Airway Immune-modifying Therapies
Am J Respir Cell Mol Biol. 2023 Aug 21. doi: 10.1165/rcmb.2023-0202MA. Online ahead of print.ABSTRACTRespiratory virus infections initiate and transmit from the upper respiratory tract (URT). Coronaviruses, including OC43, are a major cause of respiratory infection and disease. Failure to mount an effective anti-viral immune response in the nasal mucosa increases the risk of severe disease and person to person transmission highlighting the need for URT infection models to support development of nasal treatments that improve coronavirus anti-viral immunity. We aimed to determine if OC43 productively infected the mouse URT a...
Source: Mol Biol Cell - August 21, 2023 Category: Molecular Biology Authors: Jason L N Girkin Nathan E Bryant Su-Ling Loo Alan Hsu Amama Kanwal Teresa C Williams Steven Maltby Stuart G Turville Peter A B Wark Nathan W Bartlett Source Type: research